Date of Award
Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) present a novel therapy for use in Type 2 Diabetes Mellitus (T2DM) patients to reduce Hemoglobin A1c (HbA1c) and weight. GLP-1 RAs are costly medications and are not currently on the national formulary for Veterans Affairs medical centers. This study looks to explore the efficacy data in a veteran population.
Warshawsky, Isaac, "The Effects of a GLP-1 Receptor Agonist on HbA1c and Weight in Comparison to Standard Therapy in a Veteran Population" (2020). Undergraduate Honors Thesis Collection. 527.